Launch of new application enables global
access to highly recognized solid tumor profiling assay
BOSTON and ROLLE, Switzerland, Nov. 21,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native healthcare technology leader in data-driven
medicine, announced the global launch of MSK-IMPACT®
powered with SOPHiA DDM™ today from the Association for Molecular
Pathology (AMP) Annual Meeting. This innovative solution provides
organizations worldwide with the opportunity to benefit from
Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class
comprehensive genomic profiling (CGP) application on the SOPHiA
DDM™ Platform with high accuracy and efficiency.
"The launch of MSK-IMPACT® powered with SOPHiA DDM™
is another major milestone in our journey to expand access to
precision oncology globally and demonstrates our commitment to
democratizing data-driven medicine," said Philippe Menu, M.D.,
PhD., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS. "Following the successful
launch of MSK-ACCESS® powered with SOPHiA DDM™ earlier
this year, we are incredibly excited to further build on our
excellent collaboration with MSK. Launching this application is a
powerful step in our vision to decentralize access to advanced
tumor profiling technologies, making these capabilities more widely
available, especially in underserved populations."
Kojo S. J. Elenitoba-Johnson, M.D., Chair of the Department of
Pathology and Lab Medicine at MSK, added, "We share a vision with
SOPHiA GENETICS to advance precision medicine and to make our
leading tests more accessible to patients around the world."
Through MSK-IMPACT® powered with SOPHiA DDM™,
organizations can process more precise oncology analysis by
enhancing the accuracy of somatic mutation detection, including in
genes that are highly relevant for the current pharmaceutical
industry R&D pipelines, such as MTAP. The matched
tumor-normal analysis approach allows clinicians and researchers to
detect somatic mutations more confidently, minimizing the risk of
misclassifying germline variants as tumor-specific. Additionally,
institutions benefit from the global collective intelligence
created by SOPHiA GENETICS' network, allowing users to contribute
to and draw from a continuously evolving base of real-world data
and insights from diverse populations.
SOFIVA GENOMICS, a leading molecular diagnostics company in
Taiwan, is among the first to
adopt this application. The company initially partnered with SOPHiA
GENETICS in 2022 to utilize the SOPHiA DDM™ Homologous
Recombination Deficiency (HRD) Solution. Now, SOFIVA GENOMICS is
expanding its tumor profiling capabilities by adding
MSK-IMPACT® powered with SOPHiA DDM™ alongside the
liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™.
Chia-Cheng Hung, General Manager,
SOFIVA GENOMICS, commented, "Our partnership with SOPHiA GENETICS
has greatly enhanced our ability to provide localized, highly
accurate genomic testing. Access to this advanced technology
enables us to bring advanced, trusted capabilities and further our
progress on cancer research in Taiwan."
MSK-IMPACT® powered with SOPHiA DDM™ enables a more
efficient workflow, with the entire process from DNA extraction to
final report taking approximately five days. Clinicians and
researchers benefit from access to OncoKB™, MSK's Precision
Oncology Knowledge Base, which further enhances the interpretive
power of the SOPHiA DDM™ analysis through data-driven, actionable
insights. In-house analytical validation results for
MSK-IMPACT® powered with SOPHiA DDM™ showed high
concordance to the single-site MSK-IMPACT® test,
achieving:
- 99.3% positive percent agreement (PPA) for SNV/Indel
detection
- 94.6% PPA for copy number variant (CNV) detection
- 99.4% overall percent agreement (OPA) for microsatellite
instability (MSI) detection
- 98.8% OPA for tumor mutational burden (TMB)
detection.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.com, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a cloud-native healthcare technology company on a mission to
transform patient care by expanding access to data-driven medicine
globally. It is the creator of the SOPHiA DDM™ Platform, which
analyzes complex genomic and multimodal data and generates
real-time, actionable insights for a broad global network of
hospital, laboratory, and biopharma institutions. For more
information, visit SOPHiAGENETICS.com and connect with us on
LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence. Concordance
results based on analytic assessment of RUO products.
Memorial Sloan Kettering (MSK)
has institutional financial interests related to SOPHiA
GENETICS.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-launches-msk-impact-powered-with-sophia-ddm-at-amp-2024-302312292.html
SOURCE SOPHiA GENETICS